Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Restricted accessResearch articleFirst published online June, 2021
Histamine 3 receptor inverse agonist Samelisant (SUVN-G3031): Pharmacological characterization of an investigational agent for the treatment of cognitive disorders
Central histamine H3 receptors are a family of presynaptic auto and heteroreceptors. Blockade of the presynaptic H3 receptors activates the downstream pathway(s) involved in the processes of learning and memory, making it a potential therapeutic option for ameliorating cognitive dysfunction. Samelisant (SUVN-G3031) is a potent and selective inverse agonist at the H3 receptors.
Aim:
The aim of this research is to study the effects of Samelisant in diverse animal models of cognitive functions.
Methods:
The effects of Samelisant on cognitive functions were studied using social recognition, object recognition and Morris water maze tasks. Neurochemical and electrophysiological effects of Samelisant were monitored using microdialysis and electroencephalography techniques.
Results:
Samelisant showed procognitive effects in diverse animal models of cognition at doses ranging from 0.3 to 3 mg/kg, per os (p.o.) (social recognition and object recognition task). Samelisant significantly increased the brain acetylcholine levels in the cortex at doses of 10 and 20 mg/kg, p.o. In the Morris water maze task, combined administration of suboptimal doses of Samelisant and donepezil resulted in procognitive effects significantly larger than the either treatment. Similarly, Samelisant significantly potentiated the effects of donepezil on pharmacodynamic biomarkers of cognition i.e. acetylcholine levels in brain and neuronal theta oscillations.
Conclusion:
Samelisant may have potential utility in the treatment of cognitive deficits associated with hypocholinergic state.
BrownJWWhiteheadCABassoAM, et al. (2013) Preclinical evaluation of non-imidazole histamine H3 receptor antagonists in comparison to atypical antipsychotics for the treatment of cognitive deficits associated with schizophrenia. Int J Neuropsychopharmacol16: 889–904.
2.
ChangQSavageLMGoldPE (2006) Microdialysis measures of functional increases in ACh release in the hippocampus with and without inclusion of acetylcholinesterase inhibitors in the perfusate. J Neurochem97: 697–706.
3.
ClaphamJKilpatrickGJ (1992) Histamine H3 receptors modulate the release of [3H]-acetylcholine from slices of rat entorhinal cortex: Evidence for the possible existence of H3 receptor subtypes. Br J Pharmacol107: 919–923.
4.
CobosEJEntrenaJMNietoFR, et al. (2008) Pharmacology and therapeutic potential of sigma(1) receptor ligands. Curr Neuropharmacol6: 344–366.
5.
Delay-GoyetPBlanchardVSchusslerN, et al. (2016) SAR110894, a potent histamine H3-receptor antagonist, displays disease-modifying activity in a transgenic mouse model of tauopathy. Alzheimers Dement2: 267–280.
6.
EsbenshadeTABrowmanKEMillerTR, et al. (2012) Pharmacological properties and procognitive effects of ABT-288, a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther343: 233–245.
7.
EsbenshadeTAFoxGBCowartMD (2006) Histamine H3 receptor antagonists: Preclinical promise for treating obesity and cognitive disorders. Mol Interv6: 77–88.
8.
FileSEGonzalezLEAndrewsN (1998) Endogenous acetylcholine in the dorsal hippocampus reduces anxiety through actions on nicotinic and muscarinic1 receptors. Behav Neurosci112: 352–359.
9.
FlikGDremencovECremersTI, et al. (2011) The role of cortical and hypothalamic histamine-3 receptors in the modulation of central histamine neurotransmission: An in vivo electrophysiology and microdialysis study. Eur J Neurosci34: 1747–1755.
10.
FoxGBEsbenshadeTAPanJB, et al. (2005) Pharmacological properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological characterization and broad preclinical efficacy in cognition and schizophrenia of a potent and selective histamine H3 receptor antagonist. J Pharmacol Exp Ther313: 176–190.
11.
GaliciRBoggsJDAluisioL, et al. (2009) JNJ-10181457, a selective non-imidazole histamine H(3) receptor antagonist, normalizes acetylcholine neurotransmission and has efficacy in translational rat models of cognition. Neuropharmacology56: 1131–1137.
12.
GemkowMJDavenportAJHarichS, et al. (2009) The histamine H3 receptor as a therapeutic drug target for CNS disorders. Drug Discov Today14: 509–515.
13.
GhamariNZareiOArias-MontañoJA, et al. (2019) Histamine H3 receptor antagonists/inverse agonists: Where do they go?Pharmacol Ther200: 69–84.
14.
HagenowSStasiakARamsayRR, et al. (2017) Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B. Sci Rep7: 40541.
15.
HajósMSiokCJHoffmannWE, et al. (2008) Modulation of hippocampal theta oscillation by histamine H3 receptors. J Pharmacol Exp Ther324: 391–398.
16.
HerrikKFMørkARichardN, et al. (2016) The 5-HT6 receptor antagonist idalopirdine potentiates the effects of acetylcholinesterase inhibition on neuronal network oscillations and extracellular acetylcholine levels in the rat dorsal hippocampus. Neuropharmacology107: 351–363.
17.
HinoNMarumoTKotaniM, et al. (2020) A novel potent and selective histamine H3 receptor antagonist enerisant: In vitro profiles, in vivo receptor occupancy, wake-promoting and pro-cognitive effects in rodents. J Pharmacol Exp Ther375: 276–285.
18.
KuhneSWijtmansMLimHD, et al. (2011) Several down, a few to go: Histamine H3 receptor ligands making the final push towards the market?Expert Opin Investig Drugs20: 1629–1648.
19.
JinCYAnichtchikOPanulaP (2009) Altered histamine H3 receptor radioligand binding in post-mortem brain samples from subjects with psychiatric diseases. Br J Pharmacol157: 118–129.
20.
JinJMarenS (2015) Prefrontal-hippocampal interactions in memory and emotion. Front Syst Neurosci9: 170.
21.
JucaiteATakanoABoströmE, et al. (2013) AZD5213: A novel histamine H3 receptor antagonist permitting high daytime and low nocturnal H3 receptor occupancy, a PET study in human subjects. Int J Neuropsychopharmacol16: 1231–1239.
22.
ŁażewskaDKieć-KononowiczK (2018) Progress in the development of histamine H3 receptor antagonists/inverse agonists: A patent review (2013-2017). Expert Opin Ther Pat28: 175–196.
23.
LigneauXPerrinDLandaisL, et al. (2007) BF2.649 [1-{3-[3-(4-Chlorophenyl)propoxy]propyl}piperidine, hydrochloride], a nonimidazole inverse agonist/antagonist at the human histamine H3 receptor: Preclinical pharmacology. J Pharmacol Exp Ther320: 365–375.
24.
LinJSDauvilliersYArnulfI, et al. (2008) An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: Studies in orexin-/- mice and patients. Neurobiol Dis30: 74–83.
25.
McNaughtonNKocsisBHajósM (2007) Elicited hippocampal theta rhythm: A screen for anxiolytic and procognitive drugs through changes in hippocampal function?Behav Pharmacol18: 329-346.
26.
MauriceTGoguadzeN (2017) Sigma-1 (σ1) receptor in memory and neurodegenerative diseases. Handb Exp Pharmacol244: 81–108.
27.
MedhurstADAtkinsARBeresfordIJ, et al. (2007) GSK189254, a novel H3 receptor antagonist that binds to histamine H3 receptors in Alzheimer’s disease brain and improves cognitive performance in preclinical models. J Pharmacol Exp Ther321: 1032–1045.
28.
MedhurstADRobertsJCLeeJ, et al. (2009) Characterization of histamine H3 receptors in Alzheimer’s disease brain and amyloid over-expressing TASTPM mice. Br J Pharmacol157: 130–138.
29.
MonczorFFernandezN (2016) Current knowledge and perspectives on histamine H1 and H2 receptor pharmacology: Functional selectivity, receptor crosstalk, and repositioning of classic histaminergic ligands. Mol Pharmacol90: 640–648.
30.
Nieto-AlamillaGMárquez-GómezRGarcía-GálvezAM, et al. (2016) The histamine H3 receptor: Structure, pharmacology, and function. Mol Pharmacol90: 649–673.
31.
NirogiRAbrahamRBenadeV, et al. (2019a) SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: Pharmacological, behavioral, and neurochemical characterization. Behav Pharmacol30: 16–35.
32.
NirogiRKandikereVBhyrapuneniG, et al. (2012) Approach to reduce the non-specific binding in microdialysis. J Neurosci Methods209: 379–387.
33.
NirogiRMudigondaKBhyrapuneniG, et al. (2020) Safety, tolerability, and pharmacokinetics of SUVN-G3031, a novel histamine-3 receptor inverse agonist for the treatment of narcolepsy, in healthy human subjects following single and multiple oral doses. Clin Drug Investig40: 603–615.
34.
NirogiRMudigondaKKandikereV, et al. (2010) Quantification of acetylcholine, an essential neurotransmitter, in brain microdialysis samples by liquid chromatography mass spectrometry. Biomed Chromatogr24: 39–48.
35.
NirogiRShindeAMohammedAR, et al. (2019b) Discovery and development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide dihydrochloride (SUVN-G3031): A novel, potent, selective, and orally active histamine H3 receptor inverse agonist with robust wake-promoting activity. J Med Chem62: 1203–1217.
36.
PanayiFSorsABertL, et al. (2017) In vivo pharmacological profile of S 38093, a novel histamine H3 receptor inverse agonist. Eur J Pharmacol803: 1–10.
37.
ParmentierRAnacletCGuhennecC, et al. (2007) The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders. Biochem Pharmacol73: 1157–1171.
38.
PassaniMBBlandinaP (2011) Histamine receptors in the CNS as targets for therapeutic intervention. Trends Pharmacol Sci32: 242–249.
39.
PassaniMBLinJSHancockA, et al. (2004) The histamine H3 receptor as a novel therapeutic target for cognitive and sleep disorders. Trends Pharmacol Sci25: 618–625.
40.
PaxinosGWatsonC (2007) The Rat Brain in Stereotaxic Coordinates. 6th ed.New York: Elsevier.
41.
PrastHArgyriouAPhilippuA (1996) Histaminergic neurons facilitate social memory in rats. Brain Res734: 316–318.
42.
RaddatzRHudkinsRLMathiasenJR, et al. (2012) CEP-26401 (irdabisant), a potent and selective histamine H3 receptor antagonist/inverse agonist with cognition-enhancing and wake-promoting activities. J Pharmacol Exp Ther340: 124–133.
43.
ReL (1999) Modulation of acetylcholine release by presynaptic muscarinic autoreceptors. Acta Physiol Pharmacol Ther Latinoam49: 215–223.
44.
RiddyDMCookAEShacklefordDM, et al. (2019) Drug-receptor kinetics and sigma-1 receptor affinity differentiate clinically evaluated histamine H3 receptor antagonists. Neuropharmacology144: 244–255.
45.
RivkeesSA (2007) The development of circadian rhythms: From animals to humans. Sleep Med Clin2: 331–341.
46.
RomigiAVitraniGLo GiudiceT, et al. (2018) Profile of pitolisant in the management of narcolepsy: Design, development, and place in therapy. Drug Des Devel Ther12: 2665–2675.
47.
SchlickerEMalinowskaBKathmannM, et al. (1994) Modulation of neurotransmitter release via histamine H3 heteroreceptors. Fundam Clin Pharmacol8: 128–137.
48.
SchmidtCColletteFCajochenC, et al. (2007) A time to think: Circadian rhythms in human cognition. Cogn Neuropsychol24: 755–789.
49.
SchwartzJCArrangJMGarbargM, et al. (1990) Modulation of histamine synthesis and release in brain via presynaptic autoreceptors and heteroreceptors. Ann N Y Acad Sci604: 40–54.
50.
SigurdssonTDuvarciS (2016) Hippocampal-prefrontal interactions in cognition, behavior and psychiatric disease. Front Syst Neurosci9: 190.
51.
SmithDMFisherDBlierP, et al. (2016) The separate and combined effects of monoamine oxidase A inhibition and nicotine on resting state EEG. J Psychopharmacol30: 56–62.
52.
SorsAKrazemAKehrJ, et al. (2016) The synergistic enhancing-memory effect of donepezil and S 38093 (a histamine H3 antagonist) is mediated by increased neural activity in the septo-hippocampal circuitry in middle-aged mice. Front Pharmacol7: 492.
53.
SpiegelsteinOStevensJVan GervenJ, et al. (2016) Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. J Psychopharmacol30: 983–993.
54.
ThurmondRL (2015) The histamine H4 receptor: From orphan to the clinic. Front Pharmacol6: 65.
55.
TothLABhargavaP (2013) Animal models of sleep disorders. Comp Med63: 91–104.
56.
TrofimiukEBraszkoJJ (2014) Single dose of H3 receptor antagonist–ciproxifan–abolishes negative effects of chronic stress on cognitive processes in rats. Psychopharmacology (Berl)231: 209–219.
57.
ValdezPRamírezGarcíaA (2012) Circadian rhythms in cognitive performance: Implications for neuropsychological assessment. Chronophysiol Ther2: 81–92.
58.
VohoraDBhowmikM (2012) Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: Relevance to Alzheimer’s disease, ADHD, schizophrenia, and drug abuse. Front Syst Neurosci6: 72.
59.
WalfAAFryeCA (2007) The use of the elevated plus maze as an assay of anxiety-related behavior in rodents. Nat Protoc2: 322–328.
